This proposal is concerned with the origins and therapy of HER driven tumors. One aspect of our work is to develop an understanding of transcriptional processes involved in phenotype. Tumor pathogenesis involves adaptive and allelic changes as tumors evolve to a tumor resistance phenotype, a state often accompanied by abnormalities of DNA repair. Our studies, as well as those of others, have shown that both HER2/HER4 and HER2/EGFR heteromers influence levels of the transcription co-activator YAP (Yes-associated protein). YAP associates with HER4, which phosphorylates it. The phosphorylated YAP complex is transcriptionally active. Because YAP is a transcriptional co-activator, it reciprocally influences the targeted "antibody resistant" phenotype, since YAP increases expression of ligands for HER members. The phenotypic changes in HER expressing cells caused by ligands such as amphiregulin are adaptive adjustments. YAP has also been identified as relevant to pluripotency of stem cells. We and others found that increased HER signaling, in general, enhances DNA repair processes, even in the face of genotoxic injury, making cells resistant to certain cell death processes. Antibodies to HER2 reverse phenotype and limit HER2 mediated signaling induced resistance to DNA damage. Some elements of DNA repair are known in detail, and our work has led us to identify SUN protein nucleated "repair nodes" on the inner surface of the nuclear membrane, which are involved in this process. This work extends our efforts of targeted therapy of HER tumors and how to overcome therapeutic resistance. Our work will study post translational changes of YAP in HER transformed cells and elements of the YAP pathway in BT-474 breast tumor cells (HER2+, HER4+, EGFR+) that are "sensitive" and "resistant" to targeted HER therapy in order to ascertain the role of the YAP pathway in resistance to targeting small kinase inhibitors or targeted mAb. Secondly, we will examine some defined aspects of how HER signaling alters DNA repair processes. We will employ the amino terminus domain of SUN2 in yeast cells exposed to genotoxic signals to determine if this fragment limits repair. How SUN function is affected by HER mediated transformation of mammalian cells will be ascertained in vitro using BT-474 cells and a metastatic subline BT-474M, and in vivo using novel mouse strains.

Public Health Relevance

Our work focuses on defining biochemical changes that occur when breast tumor cells become resistant to current therapeutic modalities. Understanding these changes may lead to therapeutic strategies to overcome this clinical problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089481-12
Application #
8635980
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Salnikow, Konstantin
Project Start
2001-02-01
Project End
2016-03-31
Budget Start
2014-04-07
Budget End
2015-03-31
Support Year
12
Fiscal Year
2014
Total Cost
$246,179
Indirect Cost
$73,395
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lam, Lian; Czerniecki, Brian J; Fitzpatrick, Elizabeth et al. (2014) Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer. J Mol Biomark Diagn 4:151
Huang, J-M; Nagatomo, I; Suzuki, E et al. (2013) YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 32:2220-9
Du, Taofeng; Nagai, Yasuhiro; Xiao, Yan et al. (2013) Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Exp Mol Pathol 95:38-45
Berezov, A; Cai, Z; Freudenberg, J A et al. (2012) Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin. Oncogene 31:1938-48
Lam, Lian; McAndrew, Nicholas; Yee, Marla et al. (2012) Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta 1826:199-208
Zhou, Huihao; Zha, Zhao; Liu, Yang et al. (2011) Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21. J Biol Chem 286:31676-83
Liu, Qingdu; Hirohashi, Yoshihiko; Du, Xiulian et al. (2010) Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer. Exp Mol Pathol 88:225-33
Zhang, Hongtao; Berezov, Alan; Wang, Qiang et al. (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117:2051-8